

Md Asaduzzaman Khan, PhD

Assistant Professor, Department of Biochemistry and Microbiology, School of Health & Life Sciences, North South University, Dhaka-1229, Bangladesh.

Office: SAC825, Phone: +880-2-55668200 Ext: 6845 (Cell Phone: +88-01984199420)

Email: asaduzzaman.khan@northsouth.edu / asadkhanbmj@yahoo.com

Teaching area

Biochemistry, Molecular Biology, Protein and Enzyme Chemistry, Biotechnology, Physiology, Immunology, Cell Biology, Genetics

Research area

Molecular biology of cancer, obesity and lung disease; Small RNAs in disease therapeutics, Natural products and Nutraceuticals

Education

- **PhD in Biochemistry & Molecular Biology** (2013), Central South University, China]
- **MSc in Biochemistry & Molecular Biology** (2005), Jahangirnagar University, Bangladesh]
- **BSc in Biochemistry & Molecular Biology** (2004), Jahangirnagar University, Bangladesh]

Employments

- **Assistant Professor**, Biochemistry & Microbiology, North South University, Dhaka, Bangladesh (2024/01~)
- **Research Scientist**, Boston University School of Medicine, Boston, MA, USA (2023/06-2023/12)
- **Assistant Professor (Adjunct)**, Microbiology Program, Brac University, Dhaka, Bangladesh (2023/01-2023/05)
- **Professor (Research)**, Southwest Medical University, Luzhou, Sichuan, China (2017/01-2022/12)
- **Lecturer & Researcher**, Ton Duc Thang University, Ho chi Minh city, Vietnam (2016/10- 2016/12)
- **Postdoctoral Fellow**, University of Macau, Macau SAR (China) (2015/09-2016/08)
- **Postdoctoral Fellow**, Luzhou Medical College (Zhejiang University), Luzhou, China (2013/07- 2015/08)
- **Visiting Teacher**, Changsha Medical College, Hunan, China (2010/09- 2011/11)
- **Visiting Teacher**, BSMR Agricultural University, Bangladesh (2008/07- 2009/09)
- **Research Fellow**, National Mushroom Dev. & Ex. Center, Bangladesh (2005/06- 2009/08)

Research skills

In vitro: mammalian cell culture, molecular cloning, RNA expression (qRT-PCR), miRNA expression, circRNA expression, RNAi or gene knockdown by shRNA/siRNA/ASO, protein expression (Western blotting), FISH, DNA dot-blot, Immunoprecipitation, in vitro analysis of cell migration and invasion, reporter gene assay, some levels of flow cytometry & confocal microscopy. **Animal model:** Generation and maintenance of allograft breast cancer model of mice, lung injury model of mice, IT/SQ/tail-vein of mice, handling C. elegans.

Major research grant

- **Principle Investigator:** An Investigation on the molecular mechanism of anti-inflammatory effect of thymoquinone targeting small RNAs in lung injury. Funder: North South University (CTRG-24-SHLS-04) (2025-)
- **Principle Investigator:** New targets and molecular mechanism of thymoquinone in triple negative breast cancer therapeutics: Funder: National Science Foundation of China (NSFC) [2019].

Scientific Membership

- American Association for Cancer Research (AACR) (ID# 294147)
- Nature Study Society of Bangladesh

Editorial role

Editorial board member: *Mini-reviews in Medicinal Chemistry*; *Frontiers in Pharmacology*/ *Frontiers in Oncology* (Also served as editorial advisory board member in *Heliyon*; guest editor in *Frontiers in Molecular Biosciences*, *Current Medicinal Chemistry* and *Current Pharmaceutical Design*)

Research Profile

- **Google Scholar:** <https://scholar.google.com/citations?user=ZeQUb7YAAAAJ&hl=en>
- **Pubmed:** <https://www.ncbi.nlm.nih.gov/myncbi/md.%20asaduzzaman.khan.1/bibliography/public/>
- **Orcid:** <http://orcid.org/0000-0001-7851-0500>
- **Web of Science:** <https://publons.com/researcher/1269170/md-asaduzzaman-khan/>
- **SCOPUS:** <https://www.scopus.com/authid/detail.uri?authorId=8151989200>
- **Researchgate:** https://www.researchgate.net/profile/Md_Asaduzzaman_Khan

Full list of publications

Journal Papers (with recent impact factors)

1. Wan X, Wang L, **Khan MA**, Peng L, Sun X, Yi X, Wang Z, Chen K (2025). NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis. ***Cell Death & Differentiation***. Online published; doi: 10.1038/s41418-025-01483-x. {Q1; IF: 13.7}
2. Wang Z, Wan X, **Khan MA**, Peng L, Sun X, Yi X, Chen K (2024). NAT10 promotes liver lipogenesis in mouse through N4-acetylcytidine modification of Srebf1 and Scap mRNA. ***Lipids in Health and Disease***. 23:368. {Q1; IF: 3.9}
3. Wan X, Wang L, **Khan MA**, Peng L, Zhang K, Sun X, Yi X, Wang Z, Chen K (2024). Shift work promotes adipogenesis via cortisol-dependent downregulation of EGR3-HDAC6 pathway. ***Cell Death Discovery***. 10: 129. {Q1; IF: 6.1}
4. Yi X, Wan XX, **Khan MA**, Sun X, Wang Z, Chen K, Peng L (2024). Expression analysis of circRNAs in human adipogenesis. ***Diabetes Metabolic Syndrome and Obesity: Targets and Therapy***. 17: 45-54 {Q2; IF: 2.8}
5. **Khan MA**, Tania M (2023). Cordycepin and kinase inhibition in cancer. ***Drug Discovery Today***. 28(3):103481 {Q2; IF: 6.5}
6. Liu J, Wan XX, Zheng SY, He HH, **Khan MA**, Feng YX, Xiao JG, Chen Y, Hu XM, Zhang Q, Xiong K (2024). Mesenchymal Stem Cell Transplantation in Type 1 Diabetes Treatment: Current Advances and Future Opportunity. ***Current Stem Cell Research and Therapy***. 19(9):1175-1184. {Q2; IF: 2.1}
7. Sun X, Wan X, **Khan MA**, Zhang K, Yi X, Wang Z, Chen K (2023). Comprehensive analysis of circRNA expression profiles in Human Brown Adipose Tissue. ***Diabetes Metabolic Syndrome and Obesity: Targets and Therapy***. 16:469-478 {Q2; IF: 2.8}
8. He YF, Hu XM, **Khan MA**, Yu BY, Sheng YC, Xiao XZ, Wan XX, Tan SP, Xiong K (2023). HSF1 Alleviates Brain Injury by Inhibiting NLRP3-Induced Pyroptosis in a Sepsis Model. ***Mediators of Inflammation***. 2023:2252255. {Q2; 2022 IF: 4.6}.
9. Akter Z, Khan FZ, **Khan MA*** (2023). Gold nanoparticles in triple-negative breast cancer therapeutics. ***Current Medicinal Chemistry***. 30(3): 316-334 {Q1; IF: 3.5}
10. **Khan MA**, Zheng M, Fu J, Tania M, Li J, Fu J (2022). Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro. ***BMC Cancer***. 22:707 {Q2; IF: 3.4}
11. Zheng M, Mei Z, Junaid M, Tania M, Fu J, Chen H, **Khan MA*** (2022). Synergistic role of thymoquinone

- on anticancer activity of 5-fluorouracil in triple negative breast cancer cells. *Anti-Cancer Agents in Medicinal Chemistry*. 22(6):1111-1118. {Q3; IF: 2.6}
12. Wei C, **Khan MA** (equal contributor), Du J, Cheng J, Tania M, Leung E, Fu J (2022). Cordycepin inhibits triple-negative breast cancer cell migration and invasion by regulating EMT-TFs SLUG, TWIST1, SNAIL1 and ZEB1. *Frontiers in Oncology*. 12:898583. {Q2; IF: 3.5}
 13. Shariare MH, **Khan MA**, Al-Masum A, Khan JH, Uddin J, Kazi M (2022). Development of Stable Liposomal Drug Delivery System of Thymoquinone and Its In Vitro Anticancer Studies Using Breast Cancer and Cervical Cancer Cell Lines. *Molecules*. 27(19):6744. {Q1; IF: 4.2}
 14. Imani S, Becatti M, **Khan MA*** (2022). Molecular Targeted Therapy in Oncology: Lessons from Pharmacogenetics and Pharmacoeugenetics (Editorial). *Frontiers in Molecular Biosciences*. 9:822188. {Q1; IF: 3.9}
 15. Afroz R, Tanvir EM, Tania M, Fu J, Kamal MA, **Khan MA*** (2022). LPS/TLR4 pathways in breast cancer: insights into cell signaling. *Current Medicinal Chemistry*. 29(13):2274-2289. {Q1; IF: 3.5}
 16. Wan XX, Zhang DY, **Khan MA**, Zheng SY, Hu XM, Zhang Q, Yang RH, Xiong K (2022). Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta Cells Replacement. *Frontiers in Endocrinology*. 13: 859638 {Q1; IF: 3.9}
 17. Nyamsambuu A, **Khan MA**, Zhou X, Chen H (2022). Molecular mechanism of inhibitory effects of melatonin on prostate cancer cell proliferation, migration and invasion. *Plos One*. 17(1): e0261341 {Q1; IF: 2.9}
 18. Zhang K , Wan X, **Khan MA** , Sun X, Yi X, Wang Z, Chen K, Peng L (2022). Peripheral Blood circRNA Microarray Profiling Identities hsa_circ_0001831 and hsa_circ_0000867 as Two Novel circRNA Biomarkers for Early Type 2 Diabetic Nephropathy. *Diabetes Metabolic Syndrome and Obesity: Targets and Therapy*. 15: 2789-2801. {Q2; IF: 2.8}
 19. Kamal MA, **Khan MA*** (2022). Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (part V) (Editorial). *Current Pharmaceutical Design*. 28(12):947 {Q2; IF: 2.6}
 20. Nyamsambuu A, Zhou X, **Khan MA**, Ahmed A, Naranmandakh S, Fu J, Chen H (2022). Anti-Oxidant and Anticancerous Effect of Fomitopsis officinalis (Vill. ex Fr. Bond. et Sing) Mushroom on Hepatocellular Carcinoma Cells In Vitro through NF-kB Pathway. *Anti-Cancer Agents in Medicinal Chemistry*. 22(8):1561-1570 {Q3; IF: 2.6}
 21. Babu G, Bin Islam S, **Khan MA*** (2022). A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh. *Molecular Biology Reports*. 49: 6725-6739 {Q2; IF: 2.6}
 22. Tuli HS, Mistry H, Kaur G, Aggarwal D, Garg VK, Mittal S, Yerer MB, Sak K, **Khan MA** (2022). Gallic acid: a dietary polyphenol that exhibits anti-neoplastic activities by modulating multiple oncogenic targets. *Anti-Cancer Agents in Medicinal Chemistry*. 22(3):499-514 {Q3; IF: 2.6}
 23. Deng H, **Khan MA** (equal contributor), Liu X, Fu J, Mei Z (2022). Identification of SCAR markers for genetic authentication of Dendrobium nobile Lindl. *Brazilian Journal of Biology*. 82: e260394. {Q2; 2021 IF: 1.651}
 24. Islam MS, Morshed R, Babu G, **Khan MA*** (2022). The role of inflammations and EMT in carcinogenesis. *Advances in Cancer Biology – Metastasis*. 5:100055. (Q4; IF: 2.0)
 25. **Khan MA***, Bin Islam S, Rakib MU, Alam D, Hossen MM, Tania M, Asad A (2022). Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. *Coronaviruses*. 3(2):e030821188723 (Q4)
 26. Kundu S, Banna HA, Sayeed A, Begum MR, Brazendale K, Hasan MT, Habiba SJ, Abid MT, **Khan MA**, Chowdhury S, Kormoker T, Proshad R, Khan MSI (2021). Knowledge, attitudes, and preventive practices toward the COVID-19 pandemic: an online survey among Bangladeshi residents. *Journal of*

27. **Khan MA**, Kamal MA (2021). Targeting cellular signaling pathways in cancer by natural compounds (editorial). *Current Medicinal Chemistry*. 28(39): 7986-7. {Q1; IF: 3.5}
28. Tuli HS, Joshi R, Aggarwal, D, Kaur G, Kaur J, Kumar M, Parashar NC, **Khan MA**, Sak K (2021). Molecular mechanisms underlying chemopreventive potential of butein: current trends and future perspectives. *Chemico-Biological Interactions*. 350: 109699 {Q1; IF: 4.7}
29. Nyamsambuu A, Ahmed A, Khusbu FY, Oidovsambuu S, **Khan MA**, Zhou X, Fu J, Chen H (2021). Anti-oxidant and Antiproliferative Activities of Mongolian Medicinal Plant Extracts and Structure Isolation of Gnetin - H Compound. *Medicinal Chemistry*. 17(9): 963-973. {Q3; IF: 1.9}
30. Tania M, Asad A, Li T, Islam MS, Bin Islam S, Hossen MM, Bhuiyan MR, **Khan MA*** (2021). Thymoquinone against infectious diseases: perspectives in recent pandemics and future therapeutics. *Iranian Journal of Basic Medical Sciences*. 2021; 24(8): 1014-1022. {Q3; IF: 2.1}
31. Ali MY, Akter Z, Mei Z, Zheng M, Tania M, **Khan MA*** (2021). Thymoquinone in autoimmune diseases: therapeutic potential and molecular mechanisms. *Biomedicine & Pharmacotherapy*. 134: 111157 {Q1; IF: 6.9}
32. Akter Z, Ahmed FR, Tania M, **Khan MA*** (2021). Targeting inflammatory mediators: An anticancer mechanism of thymoquinone action. *Current Medicinal Chemistry*. 28(1): 80-92. {Q1; IF: 3.5}
33. Junaid M, Akter Y, Afroze SS, Tania M, **Khan MA*** (2021). Biological role of AKT, and regulation of AKT signaling pathway by thymoquinone: perspectives in cancer therapeutics. *Mini-Reviews in Medicinal Chemistry*. 21(3): 288-301. {Q2; IF: 3.3}
34. Khan MA, Kamal MA (2021). Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (part IV) (Editorial). *Current Pharmaceutical Design*. 27(33): 3501 {Q2; IF: 2.6}
35. Khan MA, Kamal MA (2021). Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (part III) (Editorial). *Current Pharmaceutical Design*. 27(32): 3423 {Q2; IF: 2.6}
36. Kamal MA, Khan MA* (2021). Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (part II) (Editorial). *Current Pharmaceutical Design*. 27(9): 1121-1122. {Q2; IF: 2.6}
37. **Khan A** (2021). Black Cumin in Fighting with Coronaviruses. *The Open Covid Journal*. 2021; 1: 189-190.
38. Hossain S, Sarkar M, Bhowmick S, Hussain J, Hasan M, Uddin B, **Khan MA**, Nahar T (2021). Acute cigarette smoke exposure induces oxidative damage and inflammation in Wistar rats: impact on lungs and erythrocytes. *African Journal of Biological Sciences*. 3(1): 120-128. (Q4)
39. Afroze SS, Junaid M, Akter Y, Tania M, Zheng M, **Khan MA*** (2020). Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics. *Drug Discovery Today*. 25(12): 2294-2306. {Q1; IF: 6.5}
40. **Kamal MA**, Khan MA* (2020). Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Editorial). *Current Pharmaceutical Design*. 26(41): 5221-5223. {Q2; IF: 2.6}
41. Shawon J, Akter Z, Hossen MM, Akter Y, Sayeed A, Junaid M, Afroze S, **Khan MA*** (2020). Current landscape of natural products against coronaviruses: perspectives in COVID-19 treatment and antiviral mechanism. *Current Pharmaceutical Design*. 26(41): 5241-5260. {Q2; IF: 2.6}
42. Fu J, Cheng J, Wei C, **Khan MA**, Jin Z, Fu J (2020). Assessing 23 Y-STR loci mutation rates in Chinese Han father-son pairs from southwestern China. *Molecular Biology Reports*. 47(10):7755-7760. {Q2; IF: 2.6}
43. Zhang L, Zhou Q, Cheng J, **Khan MA**, Fu J, Duan C, Sun S, Lv H, Fu J (2020). Targeted next-generation sequencing identified novel compound heterozygous variants in the CDH23 gene causing Usher syndrome type ID in a Chinese patient. *Frontiers in Genetics*. 11:422. {Q2; IF: 2.8}

44. **Khan MA***, Tania M (2020). Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects. **Current Medicinal Chemistry**. 27(6): 983-996 {Q1; IF: 3.5}
45. Agarwal V, Tuli HS, Thakral F, Singhal P, Agarwal D, Srivastava S, Pandey A, Sak K, Varol M, **Khan MA**, Sethi G (2020). Molecular mechanisms of action of Hesperidin in cancer: recent trends and advancements. **Experimental Biology and Medicine**. 245(5):486-497. {Q2; IF: 2.8}
46. Cheng J, Peng J, Fu J, **Khan MA**, Tan P, Wei C, Deng X, Chen H, Fu J (2020). Identification of a novel germline BRCA2 variant in a Chinese breast cancer family. **Journal of Cellular and Molecular Medicine**. 24:1676–1683 {Q2; IF: 4.3}
47. Fu J, Cheng J, Zhou Q, **Khan MA**, Duan C, Peng J, Lv H, Fu J (2020). Novel compound heterozygous nonsense variants, p.L150* and p.Y3565*, of the USH2A gene in a Chinese pedigree are associated with Usher syndrome type IIA. **Molecular Medicine Reports**. 22. 3464-3472. {Q2; IF: 3.4}
48. Liu X, Cheng J, Mei Z, Wei C, **Khan MA**, Peng J, Fu J (2020). SCAR marker for identification and discrimination of specific medicinal Lycium chinense Miller from Lycium species from ramp-PCR RAPD fragments. **3 Biotech**. 10(8):334. {Q2; IF: 2.6}
49. Mei Z, **Khan MA**, Fu J (2020). Genetic authentication of Eclipta prostrata (Asteraceae) from Penthorum chinense (Penthoraceae) by Sequence Characterized Amplified Region (SCAR) markers. **Revista de Biología Tropical**. 68(1):180-188. {Q2; IF: 0.8}
50. Liu X, Du J, **Khan MA**, Cheng J, Wei C, Mei Z, Chen H, He T, Fu J (2020). Analysis of genetic diversity and similarities between different Lycium varieties based on ISSR analysis and RAMP-PCR markers. **World Academy of Sciences Journal**. 2: 83-90. (Q3)
51. **Khan MA**, Tania M, Fu J (2019). Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics. **Drug Discovery Today**. 24(12):2315-2322. {Q1; IF: 6.5}
52. Chen Q, Liu J, Zhuang Y, Bai L, Yuan Q, Zheng S, Liao K, **Khan MA**, Wu Q, Luo C, Liu L, Wang H, Li T (2019). Identification of an IKK β inhibitor for inhibition of inflammation in vivo and in vitro. **Pharmacological Research**. 149:104440. {Q1; IF: 9.1}
53. Agarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, Varol M, Jain A, **Khan MA**, Sethi G (2019). Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. **Biomolecules**. 9(11):735. {Q1; IF: 4.8}
54. Tania M, Shawon J, Saif K, Kiefer R, Safaei Khorram M, Halim MA, **Khan MA*** (2019). Cordycepin downregulates Cdk-2 to interfere with cell cycle and increases apoptosis by generating ROS in cervical cancer cells: in vitro and in silico study. **Current Cancer Drug Targets**. 19(2): 152-159. {Q2; IF: 2.3}
55. Zhou B, Wei C, **Khan MA**, Chen H, Fu J (2019). Characterization and molecular cloning of novel isoforms of human spermatogenesis associated gene SPATA3. **Molecular Biology Reports**. 46(4):3827-3834. {Q2; IF: 2.6}
56. Islam MT, Zhou ZX, Chen F, **Khan MA**, Fu J, Chen H (2019). Targeting the Signalling Pathways Regulated by Deubiquitinases for Prostate Cancer Therapeutics. **Cell Biochemistry and Function**. 37(5): 304-319. {Q2; IF: 2.8}
57. Cheng J, Fu J, Zhou Q, Xiang X, Wei C, Yang L, **Khan MA**, Lv H, Fu J (2019). A novel splicing variant of the PRPH2 gene in a Chinese family causes autosomal dominant retinitis pigmentosa. **Journal of Cellular and Molecular Medicine**. 23: 3776–3780. {Q2; IF: 4.3}
58. Imani S, Cheng J, Fu J, Mobasher-Jannat A, Wei C, Mohazzab-Torabi S, Jadidi K, Khosravi MH, Shasaltaneh, MD, Yang L, **Khan MA**, Fu J (2019). Novel splicing variant c. 208+2T>C in BBS5 segregates with Bardet-Biedl syndrome in an Iranian family by targeted exome sequencing. **Bioscience Reports**. 39:BSR20181544. {Q1; IF: 3.8}
59. Sarkar M, Hasan M, Bhowmick S, Hussain J, Haque M, **Khan MA**, Hossain S (2019). Evaluation of the

Anti-oxidative, Erythrocyte Membrane Stabilizing Effect and Nutritional Status of Neolamarckia cadamba Fruit. **American Journal of Food and Nutrition**. 7(1):6-12.

60. Khanh TT, Lee RJ, Kilmartin PA, **Khan MA**, Safei Khorram M, Tamm T, Kiefer R (2018). Actuation increase in polypyrrole bilayer by photo-activated dopants. **Synthetic Metals**. 246:57-63. {Q1; IF: 4.4}
61. Safei Khorram M, Fatemi A, **Khan MA**, Kiefer R, Jafarnia S (2018). Potential risk of weed outbreak by increasing biochar's application rates in slow-growth legume, Lentil (Lens culinaris Medik.). **Journal of the Science of Food and Agriculture**. 98(6):2080-2088. {Q1; IF: 3.3}
62. Zondaka Z, Harjo M, **Khan MA**, Khanh TT, Tamm T, Kiefer R (2018). Optimal phosphotungstate concentration for polypyrrole linear actuation and energy storage. **Multifunctional Materials**. 1: 014003 (Q1)
63. Imani S, Cheng J, Shasaltaneh M, Wei C, Yang L, Fu S, Zou H, **Khan MA**, Zhang X, Chen H, Zhang D, Duan C, Lv H, Li Y, Chen R, Fu J (2018). Genetic identification and molecular modeling characterization reveal a novel PROM1 mutation in Stargardt4-like Macular Dystrophy. **Oncotarget**. 9(1): 122-141. {Q2; 2017 IF: 5.168}
64. Yang L, Ijaz I, Cheng J, Wei C, Tan X, **Khan MA**, Fu X, Fu J (2018). Evaluation of amplification refractory mutation system (ARMS) technique for quick and accurate prenatal gene diagnosis of CHM variant in choroideremia. **Application of Clinical Genetics**. 11:1-8. (Q2; IF: 2.6)
65. **Khan MA**, Tania M, Fu S, Fu J (2017). Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. **Oncotarget**. 8(31): 51907-51919. {Q2; 2017 IF: 5.168}
66. Li J, **Khan MA** (equal contribution), Wei C, Cheng J, Chen H, Yang L, Ijaz I, Fu J (2017). Thymoquinone inhibits the migration and invasive characteristics of cervical cancer cells SiHa and CaSki in vitro by targeting epithelial to mesenchymal transition associated transcription factors Twist1 and Zeb1. **Molecules**. 22(12): 2105. {Q1; IF: 4.2}
67. Imani S, Wei C, Cheng J, **Khan MA** (equal contribution), Fu S, Yang L, Tania M, Zhang X, Xiao X, Zhang X, Fu J (2017). MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion. **Oncotarget**. 8(13):21362-21379. {Q2; 2017 IF: 5.168}
68. Cheng J, Fu S, Wei C, Tania M, **Khan MA**, Imani S, Zhou B, Chen H, Xiao X, Wu J, Fu J (2017). Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China. **Cancer Biomarkers**. 19(1):85-92. {Q2; IF: 2.2}
69. Mei Z, Zhang X, **Khan MA**, Imani S, Liu X, Zou H, Wei C, Fu J (2017). Genetic analysis of Penthorum chinense Pursh. By improved-RAPD and ISSR in China. **Electronic Journal of Biotechnology**. 30: 6-11. {Q3; IF: 2.3}
70. Mei Z, **Khan MA**, Zhang X, Fu J (2017). Rapid and accurate genetic authentication of Penthorum chinense by improved RAPD-derived species-specific SCAR markers. **Biodiversitas**. 18(3):1243-1249. (Q2)
71. **Khan MA**, Cheng JL, Mei ZQ, Wei CL, Fu JJ (2016). Development of two novel specific SCAR markers by cloning improved RAPD fragments from the medicinal mushroom Ganoderma lucidum (Leysser: Fr) Karst. **Genetics and molecular research**. 15(3): gmr.15038536. {Q4; IF: 0.6}
72. Wei CL, Cheng JL, **Khan MA**, Yang LQ, Imani S, Chen HC, Fu JJ (2016). An improved DNA marker technique for genetic characterization using RAMP-PCR with high-GC primers. **Genetics and molecular research**. 15(3): gmr.15038721. {Q4; IF: 0.6}
73. Wei C, Cheng J, Zhou B, Zhu L, **Khan MA**, He T, Zhou S, He J, Lu S, Chen H, Zhang D, Zhao Y, Fu J (2016). Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein. **Scientific Reports**. 6: 29822. {Q1; IF: 3.8}

74. **Khan MA**, Tania M, Wei C, Mei Z, Fu S, Cheng J, Xu J, Fu J (2015). Thymoquinone inhibits Cancer metastasis by regulating TWIST1 associated with epithelial to mesenchymal transitions. **Oncotarget**. 6(23): 19580-19591. {Q2; 2017 IF: 5.168}
75. **Khan MA**, Zhu L, Tania M, Xiao X, Fu J (2015). The relationship between SPOP mutation and breast cancer in Chinese populations. **Genetics and Molecular Research**. 14(4):12362-12366. {Q4; IF: 0.6}
76. Liu X, **Khan MA**, Wei C, Cheng J, Zhang L, Fu J (2015). Establishment of stable cell line for inducing KAP1 protein expression. **Acta Biologica Hungarica**. 66(2): 161-168. {Q3; 2020 IF: 0.585}
77. Zhang C, Mei, Z, He Y, Cheng J, **Khan MA**, Luo P, Imani S, Fu J (2015). Development of SCAR markers based on improved RAPD amplification fragments and molecular cloning for authentication of three herb medicine Angelica sinensis, Angelica acutiloba and Levisticum officinale. **Natural product communications**. 10(10):1743-1747. {Q3; IF: 1.5}
78. Fu J, Khan MA, Mei Z, Tania M, Yang L, Cheng J (2015). Development of RAPD-SCAR markers for different Ganoderma species authentication by improved RAPD amplification and molecular cloning. **Genetics and Molecular Research**. 14 (2): 5667-5676. {Q4; IF: 0.6}
79. Zhou Q, Cheng J, Yang W, Tania M, Wang H, **Khan MA**, Duan C, Zhu L, Chen R, Lv H, Fu J (2015). Identification of a Novel Heterozygous Missense Mutation in the CACNA1F Gene in a Chinese Family with Retinitis Pigmentosa by Next Generation Sequencing. **BioMed Research International**. 2015: 907827. {Q2; 2022 IF: 3.2}
80. Mei Z, Zhang C, **Khan MA**, Zhu Y, Tania M, Luo P, Fu J (2015). Efficiency of improved RAPD and ISSR markers in assessing genetic diversity and relationships for Angelica sinensis (Oliv.) Diels varieties from China. **Electronic Journal of Biotechnology**. 18(2): 96-102. {Q3; IF: 2.3}
81. Mei Z, **Khan MA**, Yang L, Yang M, Fu J (2015). Genetic characterization and authentication of Gardenia jasminoides in different regions of China by using improved RAPD analysis. **Indian Journal of Experimental Biology**. 53(3): 164-169. {Q3; 2022 IF: 0.6}
82. Long Y, Cheng J, Mei Z, Zhao L, Wei C, Fu S, **Khan MA**, Fu J (2015). Genetic analysis of litchi (*Litchi chinensis* Sonn.) in southern China by improved random amplified polymorphic DNA (RAPD) and inter-simple sequence repeat (ISSR). **Molecular Biology Reports**. 42(1): 159-166. {Q2; IF: 2.6}
83. Cheng J, Long Y, **Khan MA**, Wei C, Fu S, Fu J (2015). Development and significance of RAPD-SCAR markers for Litchi chinensis Sonn. variety authentication by improved RAPD amplification and molecular cloning. **Electronic Journal of Biotechnology**. 18(1): 35-39. {Q3; IF: 2.3}
84. Tania M, **Khan MA** (equal contribution), Fu J (2014). Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. **Tumor Biology**. 35(8): 7335-7342. {Q2; 2017 IF: 3.650}
85. **Khan A**, Fu J (2014). Epigenetics of Transcription Factor Twist1 and Cancer. **JSM Clinical Oncology and Research**. 2(3): 1021.
86. Mei Z, **Khan MA**, Zeng W, Fu J (2014). DNA fingerprints of living fossil *Ginkgo biloba* by using ISSR and improved RAPD analysis. **Biochemical Systematics and Ecology**. 57: 332-337. {Q3; IF: 1.4}
87. Yang L, **Khan MA**, Mei Z, Yang M, Zhang T, Wei C, Yang W, Zhu L, Long Y, Fu J (2014). Development of RAPD-SCAR markers for *Lonicera japonica* Thunb. (Caprifoliaceae) variety authentication by improved RAPD and DNA cloning. **Revista De Biologia Tropical**. 62(4): 1649-1657. {Q2; IF: 0.8}
88. Mei Z, Yang L, **Khan MA**, Yang M, Wei C, Yang W, Peng X, Tania M, Zhang H, Li X, Fu J (2014). Genotyping of *Ganoderma* species by improved random amplified polymorphic DNA (RAPD) and inter-simple sequence repeat (ISSR) analysis. **Biochemical Systematics and Ecology**. 56: 40-48. {Q3; IF: 1.4}
89. Tania M, **Khan MA**, Xia K (2014). Recent advances in animal model experimentation in autism research. **Acta Neuropsychiatrica**. 26(5): 264-271. {Q2; IF: 2.6}

90. Fatima N, Rahman MM, **Khan MA***, Fu J (2014). A review on Ipomoea carnea: pharmacology, toxicology and phytochemistry. *Journal of Complementary and Integrative Medicine*. 11(2): 55-62. (Q2)
91. **Khan MA**, Chen HC, Zhang D, Fu J (2013). Twist: A Molecular Target in Cancer Therapeutics. *Tumor Biology*. 34(5): 2497-2506. {Q2; 2017 IF: 3.650}
92. **Khan MA**, Chen HC, Wan XX, Tania M, Xu A, Chen FZ, Zhang DZ (2013). Regulatory Effects of Resveratrol on Antioxidant Enzymes: A Mechanism of Growth Inhibition and Apoptosis Induction in Cancer Cells. *Molecules and Cells*. 35(3): 219-225. {Q1; IF: 3.7}
93. Fu J, Yang L, **Khan MA**, Mei Z (2013). Genetic characterization and authentication of *Lonicera japonica* Thunb. by using improved RAPD analysis. *Molecular Biology Reports*. 40(10): 5993-5999. {Q2; IF: 2.6}
94. Yang L, Fu S, **Khan MA**, Zeng W, Fu J (2013). Molecular cloning and development of RAPD-SCAR markers for Dimocarpus longan variety authentication. *SpringerPlus*. 2: 501. {Q4; 2017 IF: 1.130}
95. Wan XX, Chen H, **Khan MA**, Xu AH, Yang FL, Zhang YY, Zhang D. ISG15 Inhibits IFN- α Resistant Liver Cancer Cell Growth. *BioMed Research International*. 2013; 2013: 570909. {Q2; 2022 IF: 3.2}
96. Ouyang FD, Yang FL, Chen HC, **Khan MA**, Huang FM, Wan XX, Xu AH, Huang X, Zhou MJ, Fang Q, Zhang DZ (2013). Polymorphisms of DNA repair genes XPD, XRCC1 and OGG1, and lung adenocarcinoma susceptibility in Chinese population. *Tumor Biology*. 34(5): 2843-2848. {Q2; 2017 IF: 3.650}
97. Jiang B, Xiao S, **Khan MA**, Xue M (2013). Defective antioxidant systems in cervical cancer. *Tumor Biology*. 34(4): 2003-2009. {Q2; 2017 IF: 3.650}
98. Huang FM, Chen HC, **Khan MA**, Yang FL, Wan XX, Xu AH, Ou-yang FD, Zhang DZ (2013). CYP2A6, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from Central South China. *Medical Oncology*. 30(2): 521. {Q2; IF: 2.8}
99. **Khan MA**, Rahman MM, Tania M, Shoshee NF, Chen HC (2013). Antioxidative potential of *Duranta repens* (Linn.) fruits against H₂O₂ induced cell death *in vitro*. *African Journal of Traditional, Complementary and Alternative Medicine*. 10(3): 436-441. {Q2; 2016 IF: 0.553}
100. Khan MA*, Tania M, Liu R, Rahman MM (2013). *Hericium erinaceus*: an edible mushroom with medicinal values. *Journal of Complementary and Integrative Medicine*. 10(1): 253-258. (Q2)
101. Rahman MM, **Khan MA*** (2013). Anti-cancer potential of South Asian plants. *Natural Products and Bioprospecting*. 3(3): 74-88. (Q1; IF: 4.8)
102. **Khan MA***, Tania M (2012). Nutritional and Medicinal Importance of *Pleurotus* mushrooms: An Overview. *Food Reviews international*. 28(3): 313-329. {Q1; IF: 5.3}
103. Liu W, Li L, **Khan MA**, Zhu F (2012). Popular molecular markers in bacteria. *Molecular Genetics Microbiology and Virology*. 27(3): 103-107. {Q4; IF: 0.4}
104. Liu J, Chen HC, Rao ZZ, **Khan MA**, Wan XX, Xu AH, Zhang N, Zhang D (2011). Identification of heptapeptides interacting with IFN- α -sensitive CML cells. *Expert Opinion on Investigational Drugs*. 20(12): 1583-1589. {Q1; IF: 4.9}
105. Chen HC, Chen HJ, **Khan MA**, Rao ZZ, Wan XX, Tan B, Zhang DZ (2011). Genetic Mutations of p53 and k-ras in Gastric Carcinoma Patients from Hunan, China. *Tumor Biology*. 32(2): 367-373. {2017 IF: 3.650}
106. Luo YP, Chen HC, **Khan MA**, Chen FZ, Wan XX, Tan B, Ou-Yang FD, Zhang DZ (2011). Genetic polymorphisms of metabolic enzymes- CYP1A1, CYP2D6, GSTM1 and GSTT1, and gastric carcinoma susceptibility. *Tumor Biology*. 32(1): 215-222. {2017 IF: 3.650}
107. **Khan MA**, Chen HC, Tania M, Zhang DZ (2011). Anticancer activities of *Nigella sativa* (Black cumin). *African Journal of Traditional, Complementary and Alternative Medicine*. 8(5S): 226-232. {2016 IF: 0.553}

108. Khalil MI, Hoque MM, BasuniaMA, Alam N, **Khan MA*** (2011). Production of Cellulase by *Pleurotus ostreatus* and *Pleurotus sajor-caju* in Solid State Fermentation of Lignocellulosic Biomass. **Turkish Journal of Agriculture and Forestry**. 35(4): 333-341. {Q2; IF: 3.0}
109. **Khan MA***, Rahman MM, Tania M, Uddin N, Ahmed S (2011). *Pleurotus sajor-caju* and *Pleurotus florida* Mushrooms Improve Some Extent of the Antioxidant Systems in the Liver of Hypercholesterolemic Rats. **The Open Nutraceuticals Journal**. 4: 20-24.
110. Moonmoon M, Shelly NJ, **Khan MA***, Uddin MN, Hossain K, Tania M, Ahmed S (2011). Effects of different levels of wheat bran, rice bran and maize powder supplementation with saw dust on the production of shiitake mushroom (*Lentinus edodes* (Berk.) Singer). **Saudi Journal of Biological Sciences**. 18(4): 323-328. {Q1; 2022 IF: 4.4}
111. Uddin MN, Yesmin S, **Khan MA***, Moonmoon M, Tania M, Ahmed S (2011). Production of oyster mushrooms in different seasonal conditions of Bangladesh. **Journal of Scientific Research**. 3(1): 161-167
112. Mamun AA, **Khan MA** (2011). Freshwater Mussels (*Margaritifera margaritifera*): Bio-filter Against Water Pollution. **World Applied Sciences Journal**. 12(5): 580-585.
113. Tania M, **Khan MA**, Zhang H, Li J, Song Y (2010). Autotaxin: a protein with two faces. **Biochemical and Biophysical Research Communications**. 401(4): 493-497. {Q1; IF: 2.5}
114. **Khan MA**, Tania M, Zhang DZ, Chen HC (2010). Antioxidant Enzymes and Cancer. **Chinese Journal of Cancer Research**. 22(2): 87-92. {Q2; IF: 7.0}
115. Tania M, **Khan MA**, Song Y (2010). Association of Lipid Metabolism with Ovarian Cancer. **Current Oncology**. 17(5): 6-11. {Q2; 2022 IF: 2.6}
116. **Khan MA**, Tania M, Zhang DZ, Chen HC (2010). Cordyceps Mushroom: A Potent Anticancer Nutraceutical. **The Open Nutraceuticals Journal**. 3:179-183.
117. Moonmoon M, Uddin MN, Ahmed S, Shelly NJ, **Khan MA*** (2010). Cultivation of Different Strains of King Oyster Mushroom (*Pleurotus eryngii*) on Saw Dust and Rice Straw in Bangladesh. **Saudi Journal of Biological Sciences**. 17(4): 341-345. {Q1; 2022 IF: 4.4}
118. Hossain S, Khalil MI, Alam MK, **Khan MA**, Alam N (2009). Upgrading of animal feed by solid state fermentation by *Pleurotus sajor-caju*. **European Journal of Applied Science**. 1(4): 53-58
119. Alam N, Amin R, **Khan A**, Ara I, Shim MJ, Lee MW, Lee UY, Lee TS (2009). Comparative Effects of Oyster Mushrooms on Lipid Profile, Liver and Kidney Function in Hypercholesterolemic Rats. **Mycobiology**. 37(1): 37-42. {Q2; IF: 1.6}
120. **Khan MA**, Khan LA, Hossain MS, Tania M, Uddin MN (2009). Investigation on the Nutritional Composition of the common Edible and Medicinal Mushrooms Cultivated in Bangladesh. **Bangladesh Journal of Mushroom**. 3(1): 21-28
121. Khandakar J, Uddin MN, Sarker NC, Basunia MA, **Khan MA**, Khan AS (2009). Effect of Culture Media and Environmental Factors on Mycelial Growth of *Grifola frondosa*. **Bangladesh Journal of Mushroom**. 3(1): 15-20
122. Tania M, **Khan MA**, Khatun R, Rahman M, Khalil I (2009). An investigation on the nutritional composition of unconventional poultry feed resources. **Bangladesh Journal of Life Science**. 21(2): 21-28
123. Alam N, Amin R, **Khan A**, Ara I, Shim MJ, Lee MW, Lee TS (2008). Nutritional Analysis of Cultivated Mushrooms in Bangladesh- *Pleurotus ostreatus*, *Pleurotus sajor-caju*, *Pleurotus florida* and *Calocybe indica*. **Mycobiology**. 36(4): 228-232. {Q2; IF: 1.6}

124. **Khan MA**, Tania M, Amin SMR, Uddin MN (2008). An Investigation on the nutritional composition of mushroom (*Pleurotus florida*) Cultivated on Different Substrates. **Bangladesh Journal of Mushroom**. 2(2): 17-23
125. Amin SMR, Alam N, Tania M, **Khan MA** (2008). Study of Mycelial Growth of *Cordyceps sinensis* on Different Culture Media. **Bangladesh Journal of Mushroom**. 2(2): 43-48
126. **Khan MA**, Amin SMR, Uddin MN, Tania M, Alam N (2008). Comparative Study of the Nutritional Composition of Oyster Mushrooms Cultivated in Bangladesh. **Bangladesh Journal of Mushroom**. 2(1): 9-14
127. Uddin B, **Khan MA**, Moushumi SJ, Ashab I., Billah MM, Choudhuri MSK (2007). Effects of chronic administration of Jirakadyarista on the blood biochemical parameters of female rats. **Bangladesh Journal of Life Science**. 19 (2): 77-82
128. Alam N, **Khan A**, Hossain MS, Amin SMR, Khan LA (2007). Nutritional Analysis of Dietary Mushroom-*Pleurotus florida* Eger and *Pleurotus sajor-caju* (Fr.) Singer. **Bangladesh Journal of Mushroom**. 1(2): 1-7
129. Alam N, Hossain MS, Khair A, Amin SMR, **Khan A** (2007). Comparative Effects of Oyster Mushrooms on Plasma Lipid Profile of Hypercholesterolaemic Rats. **Bangladesh Journal of Mushroom**. 1(1): 15-22

Conference Papers

1. **Khan MA**, Zheng M, Fu J (2019). Epigenetic modification of oncogenes or tumor suppressor genes by thymoquinone in triple negative breast cancer. **Proceedings of Annual meeting of American Association of Cancer Research**; March 29- April 04, at Atlanta, GA, USA (Abstract No. 3834). Published in **CANCER RESEARCH** 2019; 79 (13suppl): 3834.
2. **Khan MA**, Zheng M, Fu J (2019). Upregulation of IL17RD links to anti-metastatic effect of thymoquinone in triple negative breast cancer cells. **Chinese Academic Conference on Tumor Biomarker**; December 06-08 at Wuhan, China. Abstract: 302, pp. 262.
3. Fu J, Wei C, Cheng J, **Khan MA**, Yang L, Zou H (2018). Cordycepin inhibits breast cancer migration and invasion by targeting epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs). **Proceedings of Annual meeting of American Association of Cancer Research**; April 14-18, at Chicago, IL, USA (Abstract No. 2039). Published in **CANCER RESEARCH** 2018; 78 (13suppl): 2039.
4. Li J, **Khan MA**, Wei C, Cheng J, Chen H, Fu J (2017). Thymoquinone inhibits cervical cancer metastasis in vitro by targeting epithelial to mesenchymal transition associated transcription factors Twist1 and Zeb1. **Chinese Academic Symposium on Tumor Markers**; October 12-14, 2017, at Xian, China. (2017 Abstract no. 305; Page no. 236-237)
5. **Khan MA**, Wu, F, Ying R, Gobel V, Zhang H (2016). RNAi-based screens identify tube morphogenesis genes in the *C. elegans* spermatheca. **The Allied Genetics Conference 2016**; July 13-17, 2016 at Orlando, Florida, USA (Abstract No. W4109A)
6. **Khan MA**, Wu, F, Ying R, Zhang H (2016). Identification of tube morphogenesis genes in *C. elegans* spermatheca by RNAi based screening. **3rd Macau Symposium on Biomedical Sciences**; May 23-24, 2016 at Macau SAR, China. (Abstract No. 65)
7. **Khan MA**, Tania M, Wei C, Fu J (2015). Relationship between transcription factor TWIST1 and microRNA34a in metastatic cancer cells. **Proceedings of Annual meeting of American Association of Cancer Research**; April 18-22, 2015 at Philadelphia, PA, USA (Abstract No. 1978). Published in **CANCER RESEARCH** 2015; 75 (15suppl): 1978.
8. **Khan MA**, Yang M, Wei C, Gan L, Fu J (2014). Thymoquinone downregulates n-cadherin, twist and snail expression and inhibits migration and invasion in cancer cells. **Proceedings of Annual meeting of American Association of Cancer Research**; April 05-09, 2014 at San Diego, USA (Abstract No. 5009). Published in **CANCER RESEARCH** 2014; 74(19suppl): 5009.
9. **Khan MA**, Wan XX, Xu A, Zhang DZ, Chen HC (2012). Resveratrol modifies the activity and expression of antioxidant enzymes in somatic cancer cells. **Proceedings of Annual meeting of American Association of Cancer**

Research; March 31- April 04, 2012 at Chicago, USA (Abstract no. 1997) Published in **CANCER RESEARCH** 2012; 72(8suppl):1997.

10. **Khan MA**, Wan XX, Tania M, Xu A, Zhang DZ, Chen HC (2012). Resveratrol mediated inhibition of leukemic cell growth involves the apoptotic mechanism and some extents of modification in anti-oxidant enzymes. **Proceedings of Annual meeting of National Biochemistry and Molecular Biology Academic Conference**; August 24-26, 2012 at Sichuan, China
11. 郑美玲, **Khan MA**, 刘晓燕, 付俊江 (2019). DPEP1 基因表达载体的构建及 DPEP1 蛋白的过表达研究. **Chinese Academic Conference on Tumor Biomarker**; December 06-08 at Wuhan, China. Abstract: 1692995

Book/Book chapters

1. Junaid M, Akter Y, Afrose SS, Tania M, **Khan MA*** (2020). Apoptotic cell death: important cellular process as chemotherapeutic target (chapter 4). In: *Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models* (Editor: Tuli HS). **Springer**. PP: 65-88. ISBN: 978-981-15-7585-3/ 978-981-15-7586-0.
2. Zhou J, Chen S, **Khan MA**, Xiao T, Tania M, Khan MS, Fu J (2020). Epigenetics in Triple-Negative Breast Cancer (chapter 4). In: *Triple-negative Breast Cancer* (Editor: Deng X, Tang F, Rosol TJ). **World Scientific**. PP: 71-105. ISBN: 978-981-3277-75-5/ 978-981-3277077-9.
3. **Khan MA** (2010). Nutritional composition and hypocholesterolemic effect of mushroom: *Pleurotus sajor-caju* and *Pleurotus florida*. LAP Lambert Academic Publishing GmbH & Co. KG, Saarbrücken, Germany. ISBN: 978-3-8383-9956-0.